(Circulation. 2004;109:2826-2831.)
© 2004 American Heart Association, Inc.
Reviews: Current Perspectives |
From the Cardiovascular Research Institute, MedStar Research Institute, Washington Hospital Center, Washington, DC.
Correspondence to Stephen E. Epstein, MD, Cardiovascular Research Institute, Washington Hospital Center, 110 Irving St NW, 4B-1, Washington, DC 20010. E-mail stephen.epstein@medstar.net
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Enormous advances have occurred in the understanding of the molecular and cellular mechanisms responsible for both collateral development (collaterogenesis*) and atherogenesis. This advancement has been accompanied by parallel advances in therapies designed to enhance collaterals and to inhibit the development and progression of atherosclerosis. Our laboratory has been interested in both areas, and during our work, we noticed a consistent tradeoff: Whatever intervention enhanced collaterals increased atherogenesis and visa versa. We refer to this tradeoff as the Janus phenomenon.
This observation, if correct, is of more than passing interest given the many antiatherosclerotic interventions used in patients and the proangiogenic interventions being tested that may soon be used therapeutically. Therefore, if the Janus phenomenon is real, its clinical implications would be of critical importance. Equally as important, the concept might provide mechanistic insights into both atherogenesis and collaterogenesis.
Consequently, we began to track phenomena compatible with the Janus concept. Table 1 lists a few molecules for which reasonable evidence exists relating to both their atherosclerotic and collaterogenic effects and the actions of which are compatible with the Janus phenomenon.118 Complementary to the information contained in Table 1 are the opposite concordances displayed by different mouse strains regarding collaterogenic potential versus atherogenic susceptibility. C57BL/6 mice are susceptible to atherosclerosis and are exuberant collateral formers. Conversely, Balb/C mice are resistant to atherosclerosis and have an inferior collaterogenic capacity,19,20 suggesting that genetic determinants conveying susceptibility to atherogenesis will convey an enhanced capacity for collaterogenesis and visa versa. Therefore, the Janus phenomenon, expressing
This article has been cited by other articles:
![]() |
A. Gianella, U. Guerrini, M. Tilenni, L. Sironi, G. Milano, E. Nobili, S. Vaga, M. C. Capogrossi, E. Tremoli, and M. Pesce Magnetic resonance imaging of human endothelial progenitors reveals opposite effects on vascular and muscle regeneration into ischaemic tissues Cardiovasc Res, October 31, 2009; (2009) cvp325v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Epstein, J. Zhu, A. H. Najafi, and M. S. Burnett Insights Into the Role of Infection in Atherogenesis and in Plaque Rupture Circulation, June 23, 2009; 119(24): 3133 - 3141. [Full Text] [PDF] |
||||
![]() |
Y. Zhang, D. A. Ingram, M. P. Murphy, M. R. Saadatzadeh, L. E. Mead, D. N. Prater, and J. Rehman Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1675 - H1682. [Abstract] [Full Text] [PDF] |
||||
![]() |
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen Stimulation of collateral artery growth: travelling further down the road to clinical application Heart, February 1, 2009; 95(3): 191 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rehman An Inconvenient Truth: Recognizing Individual Differences in Arteriogenesis Circ. Res., May 23, 2008; 102(10): 1146 - 1147. [Full Text] [PDF] |
||||
![]() |
S. H. Schirmer, J. O. Fledderus, P. T.G. Bot, P. D. Moerland, I. E. Hoefer, J. Baan Jr, J. P.S. Henriques, R. J. van der Schaaf, M. M. Vis, A. J.G. Horrevoets, et al. Interferon-{beta} Signaling Is Enhanced in Patients With Insufficient Coronary Collateral Artery Development and Inhibits Arteriogenesis in Mice Circ. Res., May 23, 2008; 102(10): 1286 - 1294. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sukkar, J. Jenkins, J. Sanchez, and E. M. Wagner Inhibition of CXCR2 attenuates bronchial angiogenesis in the ischemic rat lung J Appl Physiol, May 1, 2008; 104(5): 1470 - 1475. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kinnaird, E. Stabile, S. Zbinden, M.-S. Burnett, and S. E. Epstein Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions Cardiovasc Res, May 1, 2008; 78(2): 257 - 264. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Velasquez-Castano and W. R. Taylor Angiotensin II and New Vessel Formation: Aiming for the Right Oxidative Window Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 4 - 5. [Full Text] [PDF] |
||||
![]() |
V. van Weel, R.E.M. Toes, L. Seghers, M.M.L. Deckers, M.R. de Vries, P.H. Eilers, J. Sipkens, A. Schepers, D. Eefting, V.W.M. van Hinsbergh, et al. Natural Killer Cells and CD4+ T-Cells Modulate Collateral Artery Development Arterioscler Thromb Vasc Biol, November 1, 2007; 27(11): 2310 - 2318. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. van Weel, M. de Vries, P. J. Voshol, R. E. Verloop, P. H.C. Eilers, V. W.M. van Hinsbergh, J. H. van Bockel, and P. H.A. Quax Hypercholesterolemia Reduces Collateral Artery Growth More Dominantly Than Hyperglycemia or Insulin Resistance in Mice Arterioscler Thromb Vasc Biol, June 1, 2006; 26(6): 1383 - 1390. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Khurana, M. Simons, J. F. Martin, and I. C. Zachary Role of Angiogenesis in Cardiovascular Disease: A Critical Appraisal Circulation, September 20, 2005; 112(12): 1813 - 1824. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |